Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | DEGS1 | O15121 | 4/20 | 0.45 |
| ▸ | REV1 | Q9UBZ9 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15986675 | 0.88 | TSHR (0.52) | GSK3BDYRK1AALDH1A1TSHR | |
| SCHEMBL13662043 | 0.85 | TSHR (0.69) | GSK3BDYRK1AALDH1A1TSHR | |
| SCHEMBL15986800 | 0.84 | RAB9A (0.53) | GSK3BDYRK1AALDH1A1TSHRDEGS1 | |
| SCHEMBL17409778 | 0.84 | GSK3B (0.53) | GSK3BDYRK1AALDH1A1TSHRDEGS1 | |
| SCHEMBL17409801 | 0.82 | WNT1 (0.54) | GSK3BDYRK1AALDH1A1TSHRDEGS1 | |
| SCHEMBL17403529 | 0.81 | DEGS1 (0.49) | GSK3BDYRK1AALDH1A1TSHRDEGS1 | |
| SCHEMBL17409803 | 0.79 | GSK3B (0.55) | GSK3BDYRK1AALDH1A1TSHRDEGS1 | |
| SCHEMBL2619350 | 0.77 | HSD17B10 (0.57) | TSHRDEGS1 | |
| SCHEMBL655812 | 0.76 | MEN1 (0.64) | ALDH1A1JAK3 | |
| SCHEMBL22540419 | 0.75 | MAPT (0.59) | ALDH1A1DEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9433622-B2 | Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160000784-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000784-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | TBK1, TBKBP1, TYMS | GSK3B 328/4885DYRK1A 693/4885ALDH1A1 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.